Modulation of Oxidative Stress and Apoptosis of Energy Metabolism by Deferiprone From the Circulating Lymphocytes of Patients With Parkinson's Disease or Amyotrophic Lateral Sclerosis

Trial Profile

Modulation of Oxidative Stress and Apoptosis of Energy Metabolism by Deferiprone From the Circulating Lymphocytes of Patients With Parkinson's Disease or Amyotrophic Lateral Sclerosis

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 15 Mar 2017

At a glance

  • Drugs Deferiprone (Primary)
  • Indications Amyotrophic lateral sclerosis; Iron overload; Parkinson's disease
  • Focus Pharmacodynamics
  • Acronyms LymphoEnergy
  • Most Recent Events

    • 08 Mar 2017 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017.
    • 09 Sep 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top